ASH 2023 | Updates from the KarMMa-3 trial: safety profile of ide-cel in TCE R/R multiple myeloma
Rachid Baz, MD, Moffitt Cancer Center, Tampa, FL, discusses the safety profile of idecabtagene vicleucel (ide-cel) compared to standard regimens in patients with triple-class-exposed (TCE) relapsed/refractory (R/R) multiple myeloma (MM) from the Phase III KarMMa-3 trial (NCT03651128). Dr Baz shares that the trial investigated the frequency of cytopenias, infection risk, and the incidence of second primary malignancies between ide-cel and the standard of care (SoC) treatment. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: Regeneron, Pfizer, Karyopharm, Janssen, AbbVie, BMS; Honoraria: GSK, HIKMA Cancer Network, Curio Science, AHOMPR, ASH; Membership on an entity’s Board of Directors or advisory committees: Pfizer, Janssen, BMS.
